Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.
Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.
Here is a list of all the late-breaking clinical trials being presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 annual meeting Oct. 23-26, 2023, in San Francisco.
New research is providing a broader understanding of how cardiovascular disease risk manifests following pregnancy. Having obesity before and during early pregnancy appears to be a strong indicator of risk for developing future cardiovascular disease and was significantly linked with adverse outcomes during pregnancy.
The advanced algorithm achieved a sensitivity of 93% and specificity of 98%. It was trained to identify up to five different valvular diseases at the same time from a single audio clip.
